Information Provided By:
Fly News Breaks for February 27, 2018
DBVT
Feb 27, 2018 | 08:47 EDT
JMP Securities analyst Liisa Bayko said Phase 2 data for DBV Technologies' Viaskin Milk for cow's milk protein allergy showed a robust response in children at the mid-dose. However, it dropped off at higher doses and in adolescents and she would be more confident if a dose-response relationship had been seen, she tells investors. Bayko, who said she prefers to wait to gain greater conviction before increasing her 20% probability of success for Viaskin Milk, maintains her Outperform rating and $30 price target on DBV Technologies shares.
News For DBVT From the Last 2 Days
There are no results for your query DBVT